ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung - Cancer

April 5, 2023
Alex Brunelli presented on changes to SLR for lung cancer induced by the results of trials in Europe.
April 5, 2023
Jonathan Villena-Vargas presented on changes to SLR for lung cancer induced by the results of trials in the USA.
April 5, 2023
Hisao Asamura presented on changes to SLR for lung cancer induced by the results of trials in Japan.
April 5, 2023
SLR for Lung Cancer: Changes Induced by the Results of Trials
February 16, 2023
Sleeve lobectomy is preferred to pneumonectomy for centrally located lung tumors. To report on surgical outcomes of this procedure, The European Society of Thoracic Surgeons database was searched between 2007 and 2021.
February 3, 2023
Since time to surgery for lung cancer is not well established, researchers aimed to assess whether time to surgery from diagnosis correlates with outcomes like unplanned return to care, mortality, and disease recurrence.
January 6, 2023
The FDA has approved the drug Cytalux for use in lung surgery. The drug, also known as pafolacianine, binds to lung cancer cells to make them glow under infrared light.
December 9, 2022
Researchers have been awarded a grant to fund cancer vaccine research, including the development of an mRNA vaccine that would target precancerous lung lesions.
September 23, 2022
This study aimed to establish risk factors for venous thromboembolism (VTE), a significant cause of mortality in lung cancer surgical patients. Unlike in surgical specialties that have adopted postdischarge VTE prophylaxis, in thoracic surgery the evidence is scarce.
August 19, 2022
Surgical management for potentially resectable stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial.

Pages